GE Healthcare JV rolls out digital pathology software for cancer diagnosis

Omnyx CEO Mamar Gelaye

GE Healthcare ($GE) is rolling out digital pathology software that could help doctors diagnose cancer more quickly. The move comes a few months after GE launched cloud-based radiology apps to give healthcare providers more options for analysis and data storage.

Omnyx, a joint venture between GE Healthcare and the University of Pittsburgh Medical Center (UPMC), are developing software called Dynamyx that can help doctors diagnose cancer digitally. Physicians can view images and talk to one another in real-time to try to find the correct diagnosis.

"As cancer care increases in volume and complexity, the essential need for technology and innovation mounts," Omnyx CEO Mamar Gelaye said in a statement. "We at Omnyx understand the burden on clinicians and the stakes for patients. Dynamyx represents our direct response to this growing need for healthcare providers."

Omnyx kicked off operations in 2008 after GE and UPMC struck a $20 million deal. The company was aiming to create a "virtual microscope" used to scan and store images electronically.

Omnyx Pathologist Workstation--Courtesy of GE Healthcare

Omnyx has since grown by leaps and bounds, heeding the industry's call for more computer-based diagnostic and imaging tools. In March 2015, the company revealed that diagnostic lab company Clarient would use its proprietary software to help pathologists make cancer diagnoses.

"The clinical reality is that fighting cancer begins with an accurate diagnosis. Cancer diagnosis and treatment is most effective as it becomes more personalized--and that means the role of the pathologist is crucial," Clarient CMO Kenneth Bloom said at the time.

In November, GE Healthcare launched its Health Cloud with four radiology apps. Omnyx developed the apps, which include one for image postprocessing and another for storing and analyzing a patient's imaging data.

- here's the statement

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.